摘要:
A quinoline-N-oxide derivative represented by the formula: [wherein X is hydroxy, lower alkoxy, lower alkylthio, unsubstituted or substituted aralkyloxy, or unsubstituted or substituted aralkylthio; Y is a hydrogen atom or halogen atom; R, is alkylene or alkenylene having 3 to 15 carbon atoms; Z is hydroxymethyl, lower alkoxymethyl, unsubstituted or substituted aryloxymethyl, tetrahydropyranyloxymethyl, tetrahydrofuranyloxymethyl, unsubstituted or substituted arylsulfonyloxymethyl, lower alkylthiomethyl, unsubstituted or substituted arylthiomethyl, lower alkylsulfinylmethyl, unsubstituted or substituted arylsulfinylmethyl, lower alkylsulfonylmethyl, unsubstituted or substituted arylsulfonylmethyl, aminomethyl, -CH 2 NHR 2 (wherein R 2 is lower alkyl, unsubstituted or substituted aralkyl, or unsubstituted or substituted aryl), -CH 2 NR 3 R 4 , (wherein R 3 and R 4 are lower alkyl, unsubstituted or substituted aralkyl, or unsubstituted or substituted aryl), -CH 2 N + R 5 R 6 R 7 (wherein R 5 , R 6 , and R 7 are lower alkyl, unsubstituted or substituted aralkyl, or unsubstituted or substituted aryl, where the counterion is an anion of acid or a hydroxyl ion), -COR 8 (wherein R. is a hydrogen atom, lower alkyl or hydroxy), -CH(OR 9 ) 2 (wherein R. is lower alkyl), iminomethyl, hydroxyiminomethyl, or a halogen atom] and its salts, can very strongly inhibit the lipoxygenase and considerably suppress production and release of its metabolites, and thus are useful as preventive and healing agents for the diseases caused by the lipoxygenase metabolites.
摘要:
A hydroxamic acid compound represented by the general formula (I) or a salt thereof: wherein R' represents a hydrogen atom, or a substituted or unsubstituted alkanoyl group, R 2 represents an unsubstituted alkanoyl, substituted lower alkanoyl or substituted lower alkyl group, and m represents an integer of 3 to 7, which are useful for the prevention and/or treatment of diseases caused by lipoxygenase-mediated metablites.
摘要:
Disclosed are imidazonaphthyridine derivatives represented by formula (I)
wherein: R¹ represents lower alkyl or substituted or unsubstituted aryl; and X-Y-Z represents
wherein R² represents hydrogen, lower alkyl, alkenyl, aralkenyl, or -C(R⁵)H-(CH₂) n -R⁴ (wherein R⁴ represents substituted or unsubstituted aryl, substituted or unsubstituted pyridyl, substituted or unsubstituted furyl, hydroxy-substituted lower alkyl, lower alkanoyloxy, morpholino, lower alkanoyl, carboxy, lower alkoxycarbonyl, cycloalkyl, hydroxy, lower alkoxy, halogen or NR⁶R⁷ wherein R⁶ and R⁷ independently represents hydrogen or lower alkyl; R⁵ represents hydrogen, lower alkyl, or phenyl; and n represents an integer of 0 to 3); and R³ represents hydrogen, mercapto, hydroxy, lower alkyl, or aryl and pharmaceutically acceptable salts thereof. The compounds show a potent anti-inflammatory, anti-allergic and broncho-dilative activity.
摘要:
A hydroxamic acid compound represented by the general formula (I) or a salt thereof: wherein R' represents a hydrogen atom, or a substituted or unsubstituted alkanoyl group, R 2 represents an unsubstituted alkanoyl, substituted lower alkanoyl or substituted lower alkyl group, and m represents an integer of 3 to 7, which are useful for the prevention and/or treatment of diseases caused by lipoxygenase-mediated metablites.
摘要:
A preventive and healing composition for disease due to lipoxygenase metabolic products, which comprises an effective amount of a compound represented by the formula: (wherein R is an alkyl group having 1-15 carbon atoms, Y is a hydrogen atom or a halogen atom, and X is a hydroxyl group when Y is a halogen atom and X is a hydroxyl group, a lower alkoxy group, a lower alkylthio group, a benzyloxy group or a benzylthio group when Y is a hydrogen atom) and at least one pharmaceutically acceptable carrier.
摘要:
A preventive and healing composition for disease due to lipoxygenase metabolic products, which comprises an effective amount of a compound represented by the formula: (wherein R is an alkyl group having 1-15 carbon atoms, Y is a hydrogen atom or a halogen atom, and X is a hydroxyl group when Y is a halogen atom and X is a hydroxyl group, a lower alkoxy group, a lower alkylthio group, a benzyloxy group or a benzylthio group when Y is a hydrogen atom) and at least one pharmaceutically acceptable carrier.